Skip to main content
Figure 1 | Thrombosis Journal

Figure 1

From: Cost-effectiveness analysis of treatment of venous thromboembolism with rivaroxaban compared with combined low molecular weight heparin/vitamin K antagonist

Figure 1

State diagram for the economic model. The model states referred to here are described in Table 1. Note that states, On Tx-post DVT, and, PE post DVT, were specific to analyses for patients post index PE and have been omitted from the diagram. PTS risk was restricted to states with a DVT history in the PE analysis. CTEPH, chronic thromboembolic pulmonary hypertension; DVT, deep vein thrombosis; EC, extracranial; IC, intracranial; NMCR, non-major clinically relevant; PE, pulmonary embolism; PTS, post-thrombotic syndrome; rVTE, recurrent venous thromboembolic event; Tx, treatment.

Back to article page